Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hMSCs for Acute Respiratory Distress Syndrome
NCT03818854Phase 2Completed
- Start
- Nov 2019
- Primary completion
- Mar 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human mesenchymal stromal cells in acute respiratory distress syndrome (ARDS). Primary endpoint: Oxygenation Index at 36 hours. Started Nov 2019; status: completed.
02
Drugs
human mesenchymal stromal cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03818854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818854.